(Q43518070)

24 November 2017

title

Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia (English)

1 reference

24 November 2017

1 reference

1 reference

Miller M

1

1 reference

24 November 2017

Dolinar C

series ordinal

2

1 reference

24 November 2017

Cromwell W

series ordinal

3

1 reference

24 November 2017

Otvos JD

series ordinal

4

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

American Journal of Cardiology

24 November 2017

published in

1 reference

24 November 2017

volume

87

1 reference

24 November 2017

issue

2

1 reference

24 November 2017

page(s)

232-4, A9

1 reference

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Defects of lipoprotein metabolism in familial combined hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Metabolism of high density lipoprotein subfractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Management of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901327-8

10.1016/S0002-9149(00)01327-8

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference